USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer
1 - 23 . (canceled)
24 . A method for treating alcohol abuse in a patient in need thereof comprising administering to the patient 100 to 250 mg of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof.
25 . The method according to claim 24 , wherein the (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is effective to reduce alcohol consumption by the patient in comparison to a control subject that does not receive (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof.
26 . The method according to claim 24 further comprising administering another therapeutic agent.
27 . The method according to claim 26 , wherein the other therapeutic agent is an anti-alcohol agent.
28 . The method according to claim 27 , wherein the anti-alcohol agent is selected from the group consisting of disulfiram, naltrexone, acamprosate, ondansetron, sertraline, galanthamine, nalmefene, naloxone, desoxypeganine, benzodiazepines, neuroleptics, risperidone, rimonabant, trazaodone, topiramate, and aripiprazole.
29 . The method according to claim 26 , wherein the other therapeutic agent is an anti-nicotine agent.
30 . The method according to claim 26 , wherein the other therapeutic agent is an anti-opiate agent.
31 . The method according to claim 26 , wherein the other therapeutic agent is an anti-cocaine agent.
32 . The method according to claim 26 , wherein the other therapeutic agent is an anti-depressant.
33 . The method according to claim 26 , wherein the other therapeutic agent is an anti-psychotic drug.
34 . The method according to claim 26 , wherein the other therapeutic agent is an anxiolytic agent.
35 . A method for treating ethanol consumption in a patient in need thereof comprising administering to the patient 100 to 250 mg of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof.
36 . The method according to claim 35 further comprising administering another therapeutic agent.
37 . The method according to claim 36 , wherein the other therapeutic agent is an anti-alcohol agent.
38 . The method according to claim 37 , wherein the anti-alcohol agent is selected from the group consisting of disulfiram, naltrexone, acamprosate, ondansetron, sertraline, galanthamine, nalmefene, naloxone, desoxypeganine, benzodiazepines, neuroleptics, risperidone, rimonabant, trazaodone, topiramate, and aripiprazole.